[Efficacy of indinol in antirecurrence therapy of juvenile respiratory papillomatosis].
The study of indinol efficacy in antirecurrence therapy of respiratory papillomatosis was performed in 46 children aged 2-14 years. The treatment lasted at least 12 weeks. Duration of a recurrence-free period before and after indinol administration was analysed. The response was observed in 30 (65.2%) patients. In 5 (10.9%) patients the remission continued from 2 to 3 years 10 months. In 25 (54.3%) patients recurrence-free period increased 1,5-6-fold. Side effects were not registered. Simple in use, cheap, well tolerated, usable with other treatments, indinol is recommended as a method of choice in antirecurrence treatment of recurrent respiratory papillomatosis.
Soldatskiĭ
Iu L
IuL
Kiselev
V I
VI
Onufrieva
E K
EK
Steklov
A M
AM
Shchepin
N V
NV
Strygina
Iu V
IuV
Gasparian
S F
SF
Pogosova
I E
IE
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010212:Papilloma / Q000188:drug therapy* / Q000473:pathology; D010936:Plant Extracts / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D010936:Plant Extracts